Phase IIIB Switching From Intravenous to Subcutaneous Study

Phase 3 Completed 123 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether switching to subcutaneous administration of abatacept will be safe in participants with rheumatoid arthritis who previously received long-term therapy with intravenous abatacept

Timeline

Start: 2008-05
Primary completion: 2009-12
Completion: 2012-01

Publications

Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016 May 26;17:231. doi: 10.1186/s12891-016-1082-z.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abatacept	Other / unclassified	125 mg	Subcutaneous

Phase IIIB Switching From Intravenous to Subcutaneous Study

Summary

Timeline

Publications

Drugs

Indications